Providing Unique Support for Health (PUSH) Study

Identifying and Engaging Urban HIV Infected and Uninfected YBMSM in Care

Project Narrative This 5-city proposal seeks to address HIV disparities among young (ages 15-24) Black and/or Latinx men who have sex with men (YBLMSM) and transgender women (YBLTW) in a multilevel intervention to identify, engage and retain, high-risk HIV-uninfected and HIV-infected urban YBMSM/TW in the HIV prevention and treatment cascade. The mobile-enhanced engagement intervention (MEI) is driven by the expressed and self-determined needs of each HIV infected and uninfected participant and includes care navigation, engagement, treatment and adherence. MEI also includes a supplemental Screening, Brief Intervention, and Referral for Treatment (SBIRT), to support YBLMSM/TW who face barriers accessing substance use treatment. By building upon existing case management services and flexibility to be adapted across ages and maturity and for prevention services, this intervention has the ability to transform networks, HIV and prevention care in YBLMSM/TW in cities with very high primary and secondary HIV transmission.

Study Overview

Status

Completed

Conditions

Detailed Description

Project Summary The U.S. National HIV/AIDS Strategy 2020 calls for increasing access to care and improving outcomes of people living with HIV and targeting biomedical prevention efforts (including access to pre-exposure prophylaxis [PrEP]) where HIV is most heavily concentrated. Baltimore, MD; Washington, DC; Philadelphia, PA (BWP); and Tampa and St. Petersburg, FL. are disproportionately burdened by high rates of new cases of HIV infection, with disproportionate rates in young Black and/or Latinx men who have sex with men (YBLMSM) and transgender women (YBLTW) aged 15-24. High incidence underscores the need for increased identification, linkage and initiation in HIV and preventive care for YBLMSM. Grants focused on high rates directly address NIH research priorities to reduce health disparities in the incidence of HIV, in antiretroviral therapy (ART) outcomes or in high HIV prevalent or high-risk areas.

This innovative proposal seeks to test, treat and retain YBLMSM/TW living in BWP along the prevention and treatment continuum using the following aims:

Aim 1. Identify and recruit young (ages 15-24) Black and/or Latinx men who have sex with men (YBLMSM) in 3 urban cities who are (1) HIV-infected, not virally suppressed; and (2) high-risk HIV-uninfected YBLMSM, including gender variant and questioning men, using respondent driven sampling (RDS) with targeted seed identification. Assigned female sex at birth participants may be eligible to screen and participate in this aim to assist in recruiting YBLMSM/TW; Aim 2. Compare the efficacy of two study arms (mobile-enhanced engagement intervention (MEI) vs. standard of care (SOC)) to achieve sustained retention (measured by ≥ 4 follow up visits per 18-months) and engagement in HIV care (measured by durable viral suppression (HIV VL < 20 copies/ml) and substance treatment among 240 HIV-infected YBLMSM who are not virally suppressed and recruited from RDS; and Aim 3. Modify and implement mobile-enhanced intervention for 225 high-risk HIV-uninfected YBLMSM, recruited from RDS to promote linkage, retention and engagement of pre-exposure prophylaxis (PrEP) and substance treatment uptake over 18-months, comparing younger (15-19) and older (20-24) participants.

Study Type

Interventional

Enrollment (Actual)

631

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Maryland
      • Baltimore, Maryland, United States, 21287
        • Center for Adolescent and Young Adult Health at Johns Hopkins Harriet Lane

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 24 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Natal Male Inclusion Criteria:

  • Assigned male at birth
  • 15-24 years old
  • English speaking
  • Black/African American
  • Hispanic/Latino ethnicity
  • HIV positive, viral load of 20 or greater
  • HIV negative, at high risk of HIV acquisition
  • Sex with another male within last 12-months
  • No plans to move outside of the research catchment area in next 18-months
  • Able and willing to provide informed consent
  • Not currently taking pre-exposure prophylaxis (PrEP)
  • Not currently enrolled or planning to enrolled in an HIV vaccine trial
  • Not currently enrolled or planning to enroll in an HIV adherence intervention

Natal Male Exclusion Criteria:

  • Birth-identified female
  • under age 15
  • Over age 24
  • Non-English speaking
  • No sex with another male in prior 12-months
  • Not Black/African American or Hispanic identified
  • HIV-positive, virally suppressed
  • HIV-negative, not at high risk of HIV acquisition
  • Unable or unwilling to provide consent for study participation
  • Unable or unwilling to return for study visits
  • Unwilling to provide an oral, blood or urine specimen for testing
  • Currently taking pre-exposure prophylaxis (PrEP)
  • Active or previous participation in an HIV vaccine trial
  • Current participation in an adherence intervention (unless proof in the non-intervention arm)
  • plan to relocate out of Baltimore, Washington DC, or Philadelphia in next 18- months

Natal Female Inclusion Criteria:

  • Assigned female sex at birth
  • English speaking
  • 15-24 years old
  • Have friends who are gay or bisexual males or transgender females

Natal Female Exclusion Criteria:

  • Assigned male sex at birth
  • Non-English speaking
  • Under age 15
  • Over age 24
  • No report of friends who are gay or bisexual males or transgender females

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Mobile-enhanced Engagement Intervention
Mobile-enhanced engagement intervention (MEI) to support HIV-positive and high risk HIV-negative participants achieve sustained engagement and sustained retention in HIV treatment or HIV prevention (PrEP) and substance use services at 18-months.
Mobile phone based enhanced case management intervention for HIV positive & HIV negative young Black men who have sex with men.
No Intervention: Control - SOC Case Management
Standard of care (SOC) case management.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
HIV Viral Suppression
Time Frame: 18-months
Durable viral suppression (VL < 20 copies/ml)
18-months
PrEP Uptake
Time Frame: 18-months
Engagement in HIV pre-exposure prophylaxis (PrEP) services
18-months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Engagement in substance abuse treatment services
Time Frame: 6-months
Defined as at least two substance abuse treatment visits
6-months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: David Celentano, ScD, MHS, Johns Hopkins Bloomberg School of Public Health
  • Principal Investigator: Renata Sanders, MD, ScM, MPH, Johns Hopkins Bloomberg School of Public Health and JHU School of Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2017

Primary Completion (Actual)

May 28, 2021

Study Completion (Actual)

September 6, 2022

Study Registration Dates

First Submitted

June 19, 2017

First Submitted That Met QC Criteria

June 20, 2017

First Posted (Actual)

June 21, 2017

Study Record Updates

Last Update Posted (Actual)

March 31, 2023

Last Update Submitted That Met QC Criteria

March 30, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 1R01DA04308901

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

There is no plan to make individual participant data available to other researchers.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HIV-1-infection

Clinical Trials on Mobile-enhanced Engagement Intervention

3
Subscribe